CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
GARDEN CITY, N.Y. - Beyond Air, Inc. (NASDAQ:XAIR) reported a narrower-than-expected loss for its fiscal fourth quarter, sending shares soaring 15% in after-hours trading as the medical device company provided strong revenue guidance for the current year.
The company posted a loss of $0.09 per share for the quarter ended March 31, beating analyst estimates for a $0.15 per share loss. Revenue rose to $1.15 million, up from $470,000 in the same period last year, but fell short of the $1.38 million consensus forecast.
For the full fiscal year 2025, Beyond Air’s revenue jumped 220% to $3.7 million compared to $1.2 million in fiscal 2024, driven by growing demand for its LungFit PH nitric oxide delivery system.
Looking ahead, the company expects revenue of at least $1.7 million for the current quarter ending June 30, representing over 45% sequential growth. For fiscal 2026, Beyond Air guided for revenue between $12 million to $16 million.
"Our commercial momentum is building, and that progress is now being reflected in our topline results," said CEO Steve Lisi. He noted LungFit PH is now installed at over 45 U.S. hospitals, with clinicians increasingly recognizing its advantages over conventional nitric oxide delivery methods.
The company recently submitted a PMA supplement to the FDA for its second-generation LungFit PH device, which Lisi said "could be transformative for our business" if approved.
Beyond Air ended the quarter with $6.9 million in cash and marketable securities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.